Strategies for treating idiopathic pulmonary fibrosis (original) (raw)

• Crystal, R. G. & West, J. B. (eds) The Lung: Scientific Foundations (Raven, New York, 1991).
  Google Scholar
• Westall, G. P., Stirling, R. G., Cullinan, P. C. & du Bois, R. M. Interstitial Lung Disease (eds King, T. J. & Schwarz, M. I.) 332–386 (BC Decker, Hamilton, Canada, 2003).
  Google Scholar
• Vourlekis, J. S. et al. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am. J. Med. 116, 662–668 (2004).
  Article Google Scholar
• du Bois, R. M. Evolving concepts in the early and accurate diagnosis of idiopathic pulmonary fibrosis. Clin. Chest Med. 27, S17–S25 (2006).
  Article Google Scholar
• Schwarz, M. I. & King, T. E. Jr (eds). Approach to the Evaluation and Diagnosis of Interstitial Lung Disease (BC Decker, Hamilton, Canada, 2003).
  Google Scholar
• du Bois, R. M. Oxford Textbook of Medicine (eds Warrell, D. A., Cox, T. M. & Firth, J. D.) 1439–1446 (Oxford University Press, Oxford, 2003).
  Google Scholar
• du Bois, R. M. & King, T. E. Jr. Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate. Thorax 62, 1008–1012 (2007).
  Article Google Scholar
• American Thoracic Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 165, 277–304 (2002). This classification began a more logical approach to diagnosing and researching diseases that affect the gas-exchanging regions of the lungs.
• American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. Am. J. Respir. Crit. Care Med. 161, 646–664 (2000). This statement clarified what constitutes IPF and how it is distinguishable from other diffuse fibrosing lung diseases and provided the platform for all the trials of novel therapy that ensued.
• Olson, A. L. et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am. J. Respir. Crit. Care Med. 176, 277–284 (2007). This paper provides the most accurate mortality data on IPF and emphasizes that the mortality from the disease is increasing.
  Article Google Scholar
• Selman, M., King, T. E. & Pardo, A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134, 136–151 (2001). This paper stimulated more critical thinking about disease pathogenesis and highlighted an alternative paradigm to the traditional 'inflammation produces fibrosis' concept.
  Article CAS Google Scholar
• Iwai, K., Mori, T., Yamada, N., Yamaguchi, M. & Hosoda, Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am. J. Respir. Crit. Care Med. 150, 670–675 (1994).
  Article CAS Google Scholar
• Hubbard, R., Lewis, S., Richards, K., Johnston, I. & Britton, J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 347, 284–289 (1996).
  Article CAS Google Scholar
• Steele, M. P. et al. Clinical and pathologic features of familial interstitial pneumonia. Am. J. Respir. Crit. Care Med. 172, 1146–1152 (2005).
  Article Google Scholar
• Kuwano, K. et al. Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction [see comments]. Eur. Resp. J. 10, 1445–1449 (1997).
  Article CAS Google Scholar
• Ueda, T. et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am. Rev. Respir. Dis. 146, 266–268 (1992).
  Article CAS Google Scholar
• Tobin, R. W. et al. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 158, 1804–1808 (1998).
  Article CAS Google Scholar
• Raghu, G., Yang, S. T., Spada, C., Hayes, J. & Pellegrini, C. A. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 129, 794–800 (2006).
  Article Google Scholar
• Chambers, R. C. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br. J. Pharmacol. 153, S367–S378 (2008).
  Article CAS Google Scholar
• Selman, M. & Pardo, A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc. Am. Thorac. Soc. 3, 364–372 (2006).
  Article CAS Google Scholar
• Thomas, A. Q. et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am. J. Respir. Crit. Care Med. 165, 1322–1328 (2002).
  Article Google Scholar
• Wang, Y. et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am. J. Hum. Genet. 84, 52–59 (2009).
  Article CAS Google Scholar
• Kaser, A. & Blumberg, R. S. Endoplasmic reticulum stress in the intestinal epithelium and inflammatory bowel disease. Semin. Immunol. 21, 156–163 (2009).
  Article CAS Google Scholar
• Xu, C., Bailly-Maitre, B. & Reed, J. C. Endoplasmic reticulum stress: cell life and death decisions. J. Clin. Invest. 115, 2656–2664 (2005).
  Article CAS Google Scholar
• Armanios, M. Y. et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356, 1317–1326 (2007).
  Article CAS Google Scholar
• Cronkhite, J. T. et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 178, 729–737 (2008).
  Article CAS Google Scholar
• Alder, J. K. et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl Acad. Sci. USA 105, 13051–13056 (2008).
  Article CAS Google Scholar
• du Bois, R. M. Genetic factors in pulmonary fibrotic disorders. Semin. Respir. Crit. Care Med. 27, 581–588 (2006).
  Article Google Scholar
• Laurent, G. J., Chambers, R. C., Hill, M. R. & McAnulty, R. J. Regulation of matrix turnover: fibroblasts, forces, factors and fibrosis. Biochem. Soc. Trans. 35, 647–651 (2007).
  Article CAS Google Scholar
• Davies, H. R. & Richeldi, L. Idiopathic pulmonary fibrosis: current and future treatment options. Am. J. Respir. Med. 1, 211–224 (2002).
  Article Google Scholar
• Richeldi, L., Davies, H. R., Ferrara, G. & Franco, F. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. CD002880 (2003).
• Davies, H. R., Richeldi, L. & Walters, E. H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. CD003134 (2003).
• Raghu, G. et al. Azathioprine combined with prednisolone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 144, 291–296 (1991).
  Article CAS Google Scholar
• Douglas, W. W. et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Am. J. Respir. Crit. Care Med. 158, 220–225 (1998).
  Article CAS Google Scholar
• Ziesche, R., Hofbauer, E., Wittmann, K., Petkov, V. & Block, L. H. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis [see comments]. N. Engl. J. Med. 341, 1264–1269 (1999).
  Article CAS Google Scholar
• Nathan, S. D. et al. Interferon gamma-1b as therapy for idiopathic pulmonary fibrosis: an intrapatient analysis. Respiration 71, 77–82 (2004).
  Article CAS Google Scholar
• Antoniou, K. M. et al. Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur. Respir. J. 28, 496–504 (2006).
  Article CAS Google Scholar
• Raghu, G. et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 350, 125–133 (2004).
  Article CAS Google Scholar
• King, T. E. Jr et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374, 222–228 (2009). The largest study in IPF reported to date which, although negative, showed that large studies can be done in rare lung diseases.
  Article CAS Google Scholar
• King, T. E. Jr et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 177, 75–81 (2008).
  Article CAS Google Scholar
• Raghu, G., Johnson, W. C., Lockhart, D. & Mageto, Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. 159, 1061–1069 (1999).
  Article CAS Google Scholar
• Azuma, A. et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 171, 1040–1047 (2005).
  Article Google Scholar
• Demedts, M. et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 353, 2229–2242 (2005). Refs 42 and 43 are the only two published studies that show a benefit of treatment in IPF.
  Article CAS Google Scholar
• Hoyles, R. K. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 54, 3962–3970 (2006).
  Article CAS Google Scholar
• Tashkin, D. P. et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am. J. Respir. Crit. Care Med. 176, 1026–1034 (2007).
  Article CAS Google Scholar
• Tashkin, D. P. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. 354, 2655–2666 (2006).
  Article CAS Google Scholar
• Raghu, G. et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 178, 948–955 (2008).
  Article CAS Google Scholar
• Kubo, H. et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 128, 1475–1482 (2005).
  Article CAS Google Scholar
• Moeller, A., Ask, K., Warburton, D., Gauldie, J. & Kolb, M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 40, 362–382 (2008).
  Article CAS Google Scholar
• Selman, M. et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 173, 188–198 (2006).
  Article CAS Google Scholar
• Yang, I. V. et al. Gene expression profiling of familial and sporadic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 175, 45–54 (2007). This study used gene expression analysis to distinguish familial from sporadic fibrotic lung disease, an approach that might facilitate more refined disease classification.
  Article CAS Google Scholar
• Konishi, K. et al. Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 180, 167–175 (2009).
  Article CAS Google Scholar
• Boon, K. et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS ONE. 4, e5134 (2009).
  Article Google Scholar
• Pardo, A. et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med. 2, e251 (2005).
  Article Google Scholar
• Chaudhary, N. I. et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur. Respir. J. 29, 976–985 (2007).
  Article CAS Google Scholar
• Roth, G. J. et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem. 52, 4466–4480 (2009).
  Article CAS Google Scholar
• Uhal, B. D. The role of apoptosis in pulmonary fibrosis. Eur. Respir. Rev. 17, 138–144 (2008).
  Article Google Scholar
• Basseri, S., Lhotak, S., Sharma, A. M. & Austin, R. C. The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response. J. Lipid Res. 50, 2486–2501 (2009).
  Article CAS Google Scholar
• de Almeida, S. F. et al. Chemical chaperones reduce endoplasmic reticulum stress and prevent mutant HFE aggregate formation. J. Biol. Chem. 282, 27905–27912 (2007).
  Article CAS Google Scholar
• Hecker, L. et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nature Med. 15, 1077–1081 (2009).
  Article CAS Google Scholar
• Lambeth, J. D. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic. Biol. Med. 43, 332–347 (2007).
  Article CAS Google Scholar
• Lambeth, J. D., Krause, K. H. & Clark, R. A. NOX enzymes as novel targets for drug development. Semin. Immunopathol. 30, 339–363 (2008).
  Article CAS Google Scholar
• Kotani, I. et al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb. Res. 77, 493–504 (1995).
  Article CAS Google Scholar
• Belperio, J. A. et al. The role of the Th2 CC chemokine ligand CCL17 in pulmonary fibrosis. J. Immunol. 173, 4692–4698 (2004).
  Article CAS Google Scholar
• Keane, M. P., Arenberg, D. A., Moore, B. B., Addison, C. L. & Strieter, R. M. CXC chemokines and angiogenesis/angiostasis. Proc. Assoc. Am. Physicians 110, 288–296 (1998).
  CAS PubMed Google Scholar
• Moore, B. B., Keane, M. P., Addison, C. L., Arenberg, D. A. & Strieter, R. M. CXC chemokine modulation of angiogenesis: the importance of balance between angiogenic and angiostatic members of the family. J. Investig. Med. 46, 113–120 (1998).
  CAS PubMed Google Scholar
• Keane, M. P. et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J. Immunol. 159, 1437–1443 (1997).
  CAS PubMed Google Scholar
• Munger, J. S. et al. The integrin αvβ6 binds and activates latent TGF β1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319–328 (1999).
  Article CAS Google Scholar
• Horan, G. S. et al. Partial inhibition of integrin αvβ6 prevents pulmonary fibrosis without exacerbating inflammation. Am. J. Respir. Crit. Care Med. 177, 56–65 (2008).
  Article CAS Google Scholar
• Sheppard, D. Integrin-mediated activation of transforming growth factor-β1 in pulmonary fibrosis. Chest 120, S49–S53 (2001).
  Article Google Scholar
• Mercer, P. F. et al. Pulmonary epithelium is a prominent source of proteinase-activated receptor-1-inducible CCL2 in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179, 414–425 (2009).
  Article Google Scholar
• Gharaee-Kermani, M., McCullumsmith, R. E., Charo, I. F., Kunkel, S. L. & Phan, S. H. CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine 24, 266–276 (2003).
  Article CAS Google Scholar
• Jiang, D. et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J. Clin. Invest. 114, 291–299 (2004).
  Article CAS Google Scholar
• Johnson, M. A. et al. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44, 280–288 (1989).
  Article CAS Google Scholar
• Tomioka, H. et al. A pilot study of aerosolized _N_-acetylcysteine for idiopathic pulmonary fibrosis. Respirology 10, 449–455 (2005).
  Article Google Scholar
• Taniguchi, H. et al. Pirfenidone in idiopathic pulmonary fibrosis: a Phase III clinical trial in Japan. Eur. Resp. J. 8 Dec 2009 (doi: 10.1183/09031936.00005209).
  Article Google Scholar